Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding operational updates, financial performance, and corporate governance changes. Group 1: Corporate Announcements - Happiness Blue Sea expects that the film "Nanjing Photo Studio" will not have a significant impact on its operating performance due to its low investment ratio [3] - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba shipping capacity expansion project, with a total construction period of 91 months [4][5] - Yunnan City Investment elected Cui Kai as the new chairman following the resignation of Kong Weiran [6] - San Chao New Materials is planning a change in control, leading to a temporary suspension of its stock [7] - Hongxiang Co., Ltd.'s actual controller Yang Cheng has been granted bail pending trial, but this will not affect the company's daily operations [8] - Digital Certification will change its controlling shareholder to Beijing Data Group following a transfer of state-owned shares [9] - Pengding Holdings reported normal recent operations with no undisclosed significant matters [10] - Dongjie Intelligent is undergoing a potential change in its actual controller due to a planned transfer of fund shares [11] - Jin Chengzi is planning to acquire 55% of Samit’s equity, leading to a temporary stock suspension [13] - Dongxin Co., Ltd. has not yet generated revenue from its newly developed chip products [14] - Hehua Co., Ltd. is planning a change in control, with stock suspension expected [15] Group 2: Financial Performance - CATL reported a 33.02% year-on-year increase in net profit for the first half of the year, with total revenue of 178.886 billion yuan [18] - XGIMI expects a net profit of 88.6622 million yuan for the first half of the year, a significant increase of 2062.33% [19] - Changjiang Electric Power achieved a net profit of 12.984 billion yuan in the first half of the year, up 14.22% year-on-year [20] - Jinhe Biological reported a net profit of 138 million yuan for the first half of the year, a 51.52% increase [21] - Nanchip Technology anticipates a net profit decrease of 35.09% to 47.03% for the first half of the year, despite revenue growth [22] Group 3: Project and Contract Updates - Tengda Construction won a bid for the Taizhou Luqiao District Jin Qing Fishing Port shore protection project, with a bid amount of 56.0634 million yuan [23] - Sinopec Oilfield Services won a construction contract worth 3.597 billion yuan for a natural gas pipeline project [24] Group 4: Shareholding Changes - Hato Co., Ltd. announced that its shareholder Dazheng Group plans to reduce its stake by up to 1% [25] - Jiangbolong's actual controller and some directors committed not to reduce their holdings within 12 months [26] - Wansheng Co., Ltd. announced a planned reduction of up to 500,000 shares by a shareholder [27] - Desheng Technology's actual controller plans to reduce holdings by up to 3% [28] - Guangwei Composite's controlling shareholder intends to reduce its stake by up to 1.21% [30] Group 5: Fundraising Activities - Yonghui Supermarket plans to raise up to 3.992 billion yuan through a private placement to fund store upgrades and logistics improvements [31]

Important Announcements - Company Shouwei New Materials will suspend trading for inspection on July 31, 2025, due to abnormal stock price fluctuations from July 9 to July 30, 2025 [2] - Company XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of the year, a year-on-year increase of 2062.33% [4] - Company Yuntian Lifei has submitted an application for H-share issuance and listing [5] - Company Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Company Hehua Co., Ltd. is planning a change in control, leading to a suspension of trading [10] Financial Performance - Company Dingtong Technology reported a net profit of 115 million yuan for the first half of the year, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Company Jinhai Biological achieved a net profit of 138 million yuan in the first half of the year, a year-on-year increase of 51.52% [13] - Company Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of the year, a year-on-year increase of 3.01% [14] Corporate Actions - Company Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Company Jinchengzi is planning to acquire 55% of the shares of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a suspension of trading [9] - Company San Chao New Materials is also planning a change in control, resulting in a trading suspension [11] Project Investments - Company Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [8]

（文章来源：证券日报） 证券日报网讯 7月30日晚间，金河生物发布2025年半年度报告摘要称，公司2025年半年度实现营业收入 为1，390，257，781.02元，同比增长30.45%；实现归属于上市公司股东的净利润为137，918，599.30 元，同比增长51.52%。 ...

Group 1: Company Announcements - Upwind New Materials will suspend trading for stock review starting July 31, 2025, due to abnormal price fluctuations from July 9 to July 30, 2025 [2] - XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [4] - CloudWalk Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [5] - Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Hehua Co., Ltd. is undergoing a control change process, leading to a stock suspension starting July 31, 2025 [9] Group 2: Financial Performance - DingTong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Jinhe Biological achieved a net profit of 138 million yuan in the first half of 2025, a year-on-year increase of 51.52% [12] - Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of 2025, a year-on-year increase of 3.01% [13] Group 3: Corporate Developments - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a stock suspension starting July 31, 2025 [8] - SanChao New Materials is also planning a control change, resulting in a stock suspension starting July 31, 2025 [10] Group 4: Industry Developments - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project, with a total construction period of 91 months [8] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement to upgrade stores and logistics [8]

新京报贝壳财经讯7月30日，金河生物（002688）公告，2025年上半年公司实现营业收入13.9亿元，同 比增长30.45%，归母净利润1.38亿元，同比增长51.52%。公司计划不派发现金红利，不送红股，不以公 积金转增股本。 ...

Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in the veterinary pharmaceutical sector, particularly in the overseas market [1] Group 1: Financial Performance - The company achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, marking a year-on-year increase of 51.52% [1] - The overall gross margin improved by 1.25 percentage points compared to the same period last year due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Product Performance and Market Expansion - The veterinary chemical drug segment saw continuous sales growth, with the main product, Chlortetracycline, experiencing increased sales in both domestic and international markets [2] - The company expanded its market share and penetration in the domestic market, particularly in the pig farming sector, which has seen improved profitability [2] - The overseas market also showed significant growth, with sales volume doubling in other export markets compared to the previous year [2] Group 3: Vaccine and Pet Business Development - The vaccine segment is gaining market recognition, with the blue ear disease inactivated vaccine achieving a leading market share domestically [2] - The company is actively advancing its pet health business, focusing on pharmaceutical and vaccine products, with plans to launch new products [3] - The veterinary vaccine segment is expected to become a high-growth area, potentially serving as a second growth curve for the company's performance [3]

Group 1 - Company Shenzhou New Materials has experienced multiple instances of abnormal stock trading fluctuations and will be suspended from trading starting July 31, 2025, for up to three trading days [1] - The stock price of Shenzhou New Materials has increased over 1288% this year, making it the first tenfold stock of 2025 [1] - Company Yangtze Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba shipping capacity expansion project, with funding sourced from its own funds [2] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement of A-shares for store upgrades and logistics improvements [3] Group 2 - Chipsea Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy and competitiveness [4] - Zhongwang Software is facing a copyright infringement lawsuit from Autodesk in a California federal court, with the amount in dispute yet to be determined [5] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., and will suspend trading starting July 31, 2025, for up to ten trading days [6] - Nanxin Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with significant uncertainty regarding whether it constitutes a major asset restructuring [7] Group 3 - Huaheng Biological is preparing to issue H-shares and list on the Hong Kong Stock Exchange to advance its global strategy [9] - Sanchao New Materials is planning a change in company control and will suspend trading starting July 31, 2025, for up to two trading days [10] - Digital Certification's controlling shareholder will change to Beijing Data Group following a transfer of state-owned shares [11] - Hongxiang Co., Ltd.'s actual controller has been placed under residential surveillance, but this will not affect the company's normal operations [12]

Core Viewpoint - Jinhe Biological reported significant growth in its half-year performance for 2025, indicating strong operational momentum and profitability improvements [2] Financial Performance - The company's operating revenue for the first half of 2025 reached approximately 1.39 billion yuan, representing a year-on-year increase of 30.45% [2] - Net profit attributable to shareholders was around 138 million yuan, marking a year-on-year increase of 51.52% [2] - Basic earnings per share were reported at 0.1787 yuan, reflecting a year-on-year increase of 53.26% [2]

Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in its veterinary pharmaceutical segment and a favorable cost environment [1]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 1.39 billion yuan, a year-on-year increase of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, reflecting a year-on-year growth of 51.52% [1] - The overall gross margin improved by 1.25 percentage points compared to the same period last year due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Veterinary Pharmaceutical Segment - The veterinary pharmaceutical segment saw continuous sales growth, particularly in the overseas market, with the main product, Chlortetracycline, experiencing increased sales both domestically and internationally [1][2] - The company has established a diversified product structure centered around Chlortetracycline premix, which is widely used in livestock industries across various regions including China, the USA, Canada, Europe, South America, Southeast Asia, India, and Vietnam [1] - The approval of Chlortetracycline premix for use in lambs by the Ministry of Agriculture and Rural Affairs in October 2024 has expanded its application scenarios [1] Group 3: Vaccine Segment - The company operates four production bases and two research centers, with 16 vaccine products currently on the market and over 20 in development or awaiting approval [2] - The company's differentiated products, such as the blue ear disease inactivated vaccine, have achieved a leading market share domestically, with over 90% of the top 50 pig farming enterprises using its solutions [2] - The overseas vaccine platform, Famawell, is gradually entering the Chinese market, with increasing customer recognition [2] Group 4: Pet Health Business - The company is actively advancing its pet health business, focusing on pharmaceutical and vaccine products, with 15 products currently available and over ten more in the application process [3] - The pet health segment is positioned as a strategic priority for the company, with expectations for rapid growth in the veterinary vaccine sector, which is anticipated to become a significant driver of future revenue [3]

Core Viewpoint - Jinhe Biology announced the convening of its 28th meeting of the 6th Board of Directors on July 30, 2025, to review the full and summary reports of the 2025 semi-annual report [2] Revenue Composition - For the year 2024, the revenue composition of Jinhe Biology is as follows: - Veterinary chemical drugs account for 52.06% - Agricultural product processing accounts for 24.53% - Veterinary biological products account for 14.5% - Environmental protection business accounts for 6.04% - Others account for 2.54% [2]